There’s still time to contribute to the 2021 Cures4Cats Campaign focusing on Feline Hypertrophic Cardiomyopathy (HCM)!  CLICK HERE to make your tax-deductible gift and help us help cats live longer healthier lives!

EveryCat Logo

Grants

W21-032: Glucagon-like peptide 2 in cats with inflammatory bowel disease

Inflammatory bowel disease (IBD) is the most common cause of long-standing vomiting and diarrhea in cats. Treatment options are limited, and treatment is typically life-long, with many cats having a lack of response to treatment. Glucagon-like peptide-2 (GLP-2) is a hormone produced by intestinal cells in response to food. This hormone is responsible for damage repair within the intestinal tract and decreases intestinal inflammation. In people with IBD, GLP-2 is not produced in normal amounts, and treatment with GLP-2 decreases IBD severity. Cells that produce GLP-2 have been discovered in the intestinal tract of cats, and blood levels have been measured in healthy cats. However, blood levels have not been measured in cats with IBD. This study would compare concentrations of GLP-2 in the blood of cats with IBD to GLP-2 concentrations in the blood of healthy cats. This knowledge would direct future studies on the effects of disease treatment on GLP-2 concentrations and ultimately, using GLP-2 for treatment of IBD in cats.

Grant ID: W21-032

Status: Active

Year Funded: 2021

Amount awarded: $29,815

Investigator: Maria Jugan, DVM, MS, DACVIM, (SAIM), Kansas State University